NO323693B1 - Anvendelse av et preparat som omfatter lidokain sammen med ±n eller flere farmasoytisk akseptable eksipienser for fremstilling av et medikament til behandling eller forebygging av dysmenorrheatilstander. - Google Patents
Anvendelse av et preparat som omfatter lidokain sammen med ±n eller flere farmasoytisk akseptable eksipienser for fremstilling av et medikament til behandling eller forebygging av dysmenorrheatilstander. Download PDFInfo
- Publication number
- NO323693B1 NO323693B1 NO20014361A NO20014361A NO323693B1 NO 323693 B1 NO323693 B1 NO 323693B1 NO 20014361 A NO20014361 A NO 20014361A NO 20014361 A NO20014361 A NO 20014361A NO 323693 B1 NO323693 B1 NO 323693B1
- Authority
- NO
- Norway
- Prior art keywords
- sperm
- treatment
- lidocaine
- endometriosis
- dysmenorrhea
- Prior art date
Links
- 206010013935 Dysmenorrhoea Diseases 0.000 title claims abstract description 12
- 239000003814 drug Substances 0.000 title claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 6
- 239000000546 pharmaceutical excipient Substances 0.000 title claims abstract description 6
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 title claims description 40
- 229960004194 lidocaine Drugs 0.000 title claims description 39
- 238000011282 treatment Methods 0.000 title claims description 24
- 208000005171 Dysmenorrhea Diseases 0.000 title claims description 13
- 230000002265 prevention Effects 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 claims description 12
- 230000003054 hormonal effect Effects 0.000 claims description 9
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 24
- 238000000034 method Methods 0.000 abstract description 14
- 206010036618 Premenstrual syndrome Diseases 0.000 abstract description 13
- 239000003589 local anesthetic agent Substances 0.000 abstract description 8
- 210000003101 oviduct Anatomy 0.000 abstract description 8
- 230000035558 fertility Effects 0.000 abstract description 7
- 210000003200 peritoneal cavity Anatomy 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 36
- 210000003567 ascitic fluid Anatomy 0.000 description 35
- 201000009273 Endometriosis Diseases 0.000 description 29
- 238000011534 incubation Methods 0.000 description 22
- 206010057249 Phagocytosis Diseases 0.000 description 17
- 230000008782 phagocytosis Effects 0.000 description 17
- 210000000265 leukocyte Anatomy 0.000 description 16
- 208000000509 infertility Diseases 0.000 description 13
- 235000002639 sodium chloride Nutrition 0.000 description 12
- 230000036512 infertility Effects 0.000 description 11
- 231100000535 infertility Toxicity 0.000 description 11
- 230000016087 ovulation Effects 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- 230000035935 pregnancy Effects 0.000 description 7
- 230000000750 progressive effect Effects 0.000 description 7
- 230000002357 endometrial effect Effects 0.000 description 6
- 231100000502 fertility decrease Toxicity 0.000 description 6
- 230000004720 fertilization Effects 0.000 description 6
- 230000004899 motility Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000004809 Teflon Substances 0.000 description 5
- 229920006362 Teflon® Polymers 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 4
- 238000003744 In vitro fertilisation Methods 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102000009151 Luteinizing Hormone Human genes 0.000 description 4
- 108010073521 Luteinizing Hormone Proteins 0.000 description 4
- 102100036154 Platelet basic protein Human genes 0.000 description 4
- 229960005015 local anesthetics Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002357 laparoscopic surgery Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940040129 luteinizing hormone Drugs 0.000 description 3
- 210000000287 oocyte Anatomy 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- 206010034238 Pelvic adhesions Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001109 blastomere Anatomy 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- -1 for example Chemical class 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- 229940099552 hyaluronan Drugs 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical class [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229960003608 clomifene Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical class C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001207 effect on phagocytes Effects 0.000 description 1
- 230000000687 effect on sperms Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940071308 lidocaine 10 mg/ml Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/800,737 US5977143A (en) | 1997-02-15 | 1997-02-15 | Medicament against infertility which reduces phagocytosis of spermatozoa in women |
US26550299A | 1999-03-10 | 1999-03-10 | |
PCT/US2000/003782 WO2000053183A1 (fr) | 1997-02-15 | 2000-02-12 | Medicament contre la dysmenorrhee et le syndrome premenstruel |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20014361D0 NO20014361D0 (no) | 2001-09-07 |
NO20014361L NO20014361L (no) | 2001-11-02 |
NO323693B1 true NO323693B1 (no) | 2007-06-25 |
Family
ID=26951241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20014361A NO323693B1 (no) | 1997-02-15 | 2001-09-07 | Anvendelse av et preparat som omfatter lidokain sammen med ±n eller flere farmasoytisk akseptable eksipienser for fremstilling av et medikament til behandling eller forebygging av dysmenorrheatilstander. |
Country Status (8)
Country | Link |
---|---|
US (2) | US6835388B2 (fr) |
EP (1) | EP1158978B1 (fr) |
AT (1) | ATE305784T1 (fr) |
AU (1) | AU774046B2 (fr) |
CA (1) | CA2364470A1 (fr) |
ES (1) | ES2249250T3 (fr) |
NO (1) | NO323693B1 (fr) |
WO (1) | WO2000053183A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000053183A1 (fr) * | 1997-02-15 | 2000-09-14 | Edelstam Inc. | Medicament contre la dysmenorrhee et le syndrome premenstruel |
US20080182841A1 (en) * | 2001-10-29 | 2008-07-31 | Levine Howard L | Vaginally administered anti-dysrhythmic agents for treating pelvic pain |
US20040142968A1 (en) * | 2003-01-17 | 2004-07-22 | Donald Price | Method and kit for treating lower bowel pain |
US7623976B2 (en) * | 2003-06-24 | 2009-11-24 | Cidra Corporate Services, Inc. | System of distributed configurable flowmeters |
WO2010099508A1 (fr) * | 2009-02-26 | 2010-09-02 | Theraquest Biosciences, Inc. | Compositions pharmaceutiques orales à libération prolongée de 3-hydroxy-n-méthylmorphinane et procédé d'utilisation |
US9849102B2 (en) | 2010-05-19 | 2017-12-26 | Isifer Ab | Treatment for reducing inflammation |
US9440671B2 (en) * | 2012-09-20 | 2016-09-13 | Polaris Industries Inc. | Vehicle |
RU2683203C2 (ru) | 2013-12-31 | 2019-03-26 | Эбботт Дайабитиз Кэр Инк. | Снабженный автономным питанием датчик аналита и использующие его устройства |
CA3002515C (fr) * | 2015-10-23 | 2024-01-02 | Isifer Ab | Composition pour le traitement de l'infertilite chez le sujet de sexe feminin |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3964563A (en) * | 1975-01-29 | 1976-06-22 | Allen Carling D | Wheel-support structure in vehicles |
US4207891A (en) * | 1978-10-10 | 1980-06-17 | Population Research Incorporated | Dispensing instrument with supported balloon |
US4780480A (en) * | 1983-07-14 | 1988-10-25 | Syntex (U.S.A.) Inc. | Aroyl benzofuran and benzothiophene acetic and propionic acids |
US5534242A (en) * | 1994-05-02 | 1996-07-09 | Henry; Richard A. | Lidocaine-vasoconstrictor aerosol preparation |
US5977143A (en) * | 1997-02-15 | 1999-11-02 | Edelstam; Greta | Medicament against infertility which reduces phagocytosis of spermatozoa in women |
WO2000053183A1 (fr) * | 1997-02-15 | 2000-09-14 | Edelstam Inc. | Medicament contre la dysmenorrhee et le syndrome premenstruel |
US6197327B1 (en) * | 1997-06-11 | 2001-03-06 | Umd, Inc. | Device and method for treatment of dysmenorrhea |
KR20150067397A (ko) | 2002-11-15 | 2015-06-17 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 금속 아미디네이트를 이용한 원자층 증착법 |
-
2000
- 2000-02-12 WO PCT/US2000/003782 patent/WO2000053183A1/fr active IP Right Grant
- 2000-02-12 EP EP00911804A patent/EP1158978B1/fr not_active Expired - Lifetime
- 2000-02-12 AT AT00911804T patent/ATE305784T1/de not_active IP Right Cessation
- 2000-02-12 AU AU33637/00A patent/AU774046B2/en not_active Expired
- 2000-02-12 CA CA002364470A patent/CA2364470A1/fr not_active Abandoned
- 2000-02-12 ES ES00911804T patent/ES2249250T3/es not_active Expired - Lifetime
-
2001
- 2001-09-07 NO NO20014361A patent/NO323693B1/no not_active IP Right Cessation
-
2002
- 2002-08-02 US US10/211,048 patent/US6835388B2/en not_active Expired - Lifetime
- 2002-08-02 US US10/211,050 patent/US6716446B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ATE305784T1 (de) | 2005-10-15 |
AU774046B2 (en) | 2004-06-17 |
CA2364470A1 (fr) | 2000-09-14 |
NO20014361D0 (no) | 2001-09-07 |
WO2000053183A1 (fr) | 2000-09-14 |
ES2249250T3 (es) | 2006-04-01 |
US20030004213A1 (en) | 2003-01-02 |
AU3363700A (en) | 2000-09-28 |
EP1158978A4 (fr) | 2004-03-17 |
EP1158978A1 (fr) | 2001-12-05 |
NO20014361L (no) | 2001-11-02 |
US6716446B2 (en) | 2004-04-06 |
US20030008916A1 (en) | 2003-01-09 |
EP1158978B1 (fr) | 2005-10-05 |
US6835388B2 (en) | 2004-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101490851B1 (ko) | 수성 보습제와 윤활제 및 이들의 용도 | |
NO323693B1 (no) | Anvendelse av et preparat som omfatter lidokain sammen med ±n eller flere farmasoytisk akseptable eksipienser for fremstilling av et medikament til behandling eller forebygging av dysmenorrheatilstander. | |
WO2006089561A1 (fr) | Compositions pharmaceutiques contenant des acides organiques utiles pour le ramollissement et la maturation du col de l’uterus. | |
CA2280685C (fr) | Medicament utilise pour lutter contre l'infecondite et amener a la fecondite | |
RU2309744C1 (ru) | Способ лечения послеродового эндометрита | |
RU2390339C1 (ru) | Способ лечения хронических рецидивирующих урогенитальных бактериальных и вирусных заболеваний | |
Elkholi et al. | The impact of timing of insemination in relation to ovulation on the cycle pregnancy rate of intrauterine insemination and intrauterine tuboperitoneal insemination in unexplained infertility | |
US20200121751A1 (en) | Abortion medications and administration method thereof | |
Gregoriou et al. | A randomized comparison of intrauterine and intraperitoneal insemination in the treatment of infertility | |
DE60022988T2 (de) | Medikament gegen dysmenorrhoe und premenstruelles syndrom enthaltend lidocain | |
JP7276806B2 (ja) | 女性対象における不妊症の治療ための組成物 | |
MXPA99007534A (en) | A medicament against infertility and for increasing fertility | |
Kunev et al. | Preliminary results from research on the factors affecting the success of intrauterine insemination procedures | |
Rioux et al. | Diog~ ne Cloutier Pierre Dupont Mich~ le Boulanger Vincent Bergeron | |
Allahbadia et al. | Fallopian Tube Sperm Perfusion | |
Bocca | 10 Intrauterine Insemination | |
SUNDE et al. | Is the fallopian tube better than the uterus? Evidence on intrauterine insemination versus fallopian sperm perfusion | |
Agha Hosseini et al. | Comparison of pregnancy and implantation rates in zygote intrafallopian transfer and uterine embryo transfer for nontubal infertility | |
Zuluaga Velez | Pre-and post-synchronization methodologies to enhance the efficiency of fixed timed artificial insemination in pharmacologically-controlled breeding systems with Bos indicus-influenced cattle | |
WO2001080861A1 (fr) | Sterilite ou augmentation de la fecondite |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |